Heartflow (NASDAQ:HTFL) Price Target Raised to $70.00

Heartflow (NASDAQ:HTFL) had its target price boosted by investment analysts at Stifel Nicolaus from $45.00 to $70.00 in a research note issued on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus‘s price objective indicates a potential upside of 16.82% from the stock’s current price.

Other research analysts have also issued research reports about the stock. Piper Sandler reissued an “overweight” rating and issued a $64.00 price target (up from $45.00) on shares of Heartflow in a research report on Tuesday, October 20th. Wall Street Zen downgraded Heartflow from a “buy” rating to a “hold” rating in a report on Saturday, November 7th. Morgan Stanley upped their price objective on Heartflow from $35.00 to $40.00 and gave the company an “equal weight” rating in a research note on Friday, August 14th. UBS Group assumed coverage on Heartflow in a report on Wednesday, September 9th. They issued a “neutral” rating and a $55.00 target price for the company. Finally, Robert W. Baird raised their target price on Heartflow from $56.00 to $68.00 and gave the stock an “outperform” rating in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $54.62.

Heartflow Stock Performance

Shares of HTFL stock opened at $59.92 on Friday. Heartflow has a 52-week low of $20.13 and a 52-week high of $60.65. The stock has a market cap of $5.21 billion, a price-to-earnings ratio of -32.74 and a beta of 2.50. The firm has a fifty day moving average of $51.93 and a 200-day moving average of $35.14.

Heartflow (NASDAQ:HTFL) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.15. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The company had revenue of $72.86 million during the quarter. During the same period in the previous year, the business posted ($0.27) earnings per share. On average, sell-side analysts predict that Heartflow will post -0.75 earnings per share for the current year.

Insider Buying and Selling at Heartflow

In other news, CFO Vikram Verghese sold 29,714 shares of Heartflow stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $50.06, for a total value of $1,487,482.84. Following the completion of the transaction, the chief financial officer owned 184,789 shares in the company, valued at approximately $9,250,537.34. The trade was a 13.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Farquhar sold 38,900 shares of the business’s stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $49.57, for a total value of $1,928,273.00. Following the completion of the transaction, the chief executive officer directly owned 283,014 shares in the company, valued at $14,029,003.98. The trade was a 12.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 332,403 shares of company stock worth $16,602,786 over the last ninety days. Corporate insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Heartflow

A number of hedge funds and other institutional investors have recently bought and sold shares of HTFL. First Trust Advisors LP acquired a new position in shares of Heartflow during the third quarter worth approximately $1,931,000. Teachers Retirement System of The State of Kentucky bought a new stake in shares of Heartflow during the third quarter valued at approximately $1,684,000. Allworth Financial LP grew its stake in shares of Heartflow by 116.4% during the third quarter. Allworth Financial LP now owns 1,145 shares of the company’s stock valued at $57,000 after purchasing an additional 616 shares during the last quarter. Pier 88 Investment Partners LLC acquired a new stake in shares of Heartflow in the third quarter valued at approximately $174,000. Finally, M&G PLC acquired a new stake in shares of Heartflow in the third quarter valued at approximately $15,978,000.

More Heartflow News

Here’s some of the latest news about HTFL:

• Positive Sentiment: Third-quarter revenue rose 57% year over year to $72.9 million, exceeding the roughly $65.2 million analyst estimate. The loss was $0.03 per share, narrower than both the expected $0.18 loss and the $0.27 loss a year earlier. HeartFlow Reports Q3 Loss, Beats Revenue Estimates
• Positive Sentiment: Heartflow raised its 2026 revenue guidance to $262 million–$264 million, above the approximately $248.6 million consensus estimate. The higher outlook may signal stronger growth expectations. Heartflow Expects 2026 Revenue of $262M–$264M
• Negative Sentiment: CEO insider selling may weigh on sentiment: the CEO sold $2.17 million of Heartflow stock. A sale by itself does not establish the reason for the transaction. Heartflow CEO Sells $2.17 Million in Stock

Heartflow Company Profile

HeartFlow, Inc. is a medical technology company that develops noninvasive tools to help clinicians assess coronary artery disease. Its platform analyzes coronary CT angiography scans to create personalized models of a patient’s coronary arteries and provide information that can support diagnosis and treatment planning. The company’s offerings include HeartFlow FFR CT Analysis, which estimates blood flow and the effects of artery narrowing, and tools for assessing coronary plaque. The technology combines medical imaging with computational analysis and artificial intelligence, giving clinicians information without requiring an invasive procedure to measure blood flow.